Rate My Professor Arun Sanyal

Arun J. Sanyal, M.D., is a Professor of Medicine, Physiology, and Molecular Pathology in the Division of Gastroenterology, Hepatology, and Nutrition at Virginia Commonwealth University School of Medicine. He currently serves as Chief of the Division of Gastroenterology, Hepatology, and Nutrition at VCU/VCUHealth and Director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health. Sanyal has been a faculty member at VCU since 1989. He earned his MBBS from the University of Delhi in 1981, completed his residency at Texas Tech University Health Sciences Center at Amarillo, and his fellowship at VCU Medical Center. He holds the Reno Vlahcevic Professor of Medicine position.

Sanyal's research specializations encompass all aspects of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), liver fibrosis, portal hypertension, complications of cirrhosis, and end-stage liver disease. He has received continuous NIH funding since 1995 and chairs the NIH NASH Clinical Research Network, the NIMBLE consortium, and the Liver Forum for NASH and fibrosis. With over 350 peer-reviewed publications and an h-index of 116, key works include "Design and validation of a histological scoring system for nonalcoholic fatty liver disease" (2005), "The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases" (2018), and "A multisociety Delphi consensus statement on new fatty liver disease nomenclature" (2023). His influence is evident in leadership roles such as past President of the American Association for the Study of Liver Diseases, founding member of the American Board of Internal Medicine Transplant Hepatology board, and chair of the NIH Hepatobiliary Pathophysiology Study Section. Major awards include the Distinguished Mentorship Award from the American Gastroenterological Association, Distinguished Scientific Achievement Award from the American Liver Foundation (2017), and Distinguished Achievement Award from AASLD (2018). Ranked in the top 0.01% of medical scientists, Sanyal leads phase 2B and 3 clinical trials for NASH and liver disease complications.